Top Injectable Manufacturer in Cameroon – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 21 hours ago
- 9 min read
Last Updated: July 24, 2026
TL;DR: Cameroon is a market of roughly 30 to 31 million people that imports the overwhelming majority of the medicines it consumes — local production covers only about 5% and there is no domestic maker of small-volume sterile injectables. Demand is heavy: Cameroon is one of the world’s eleven High Burden to High Impact malaria countries, with an estimated 7.6 million cases and around 11,700 deaths in 2024; cancer already accounts for roughly 19,600 new cases and 12,800 deaths a year; and non-communicable diseases now cause about a third of all deaths. Market access runs through the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML) within the Ministry of Public Health, which grants the Autorisation de Mise sur le Marché on a CTD dossier built to the CEMAC/OCEAC-harmonised requirements. A product must be imported through a locally licensed, pharmacist-led établissement pharmaceutique under a Visa Technique d’Importation, and — because Cameroon is not a party to the Hague Apostille Convention — the Certificate of Pharmaceutical Product and GMP certificate require full consular legalisation rather than an apostille. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to over 30 countries, and supports Cameroonian partners with CTD/CEMAC dossiers, consular-legalised documentation, French artwork and Zone IVb stability packages.
Key Takeaways
Regulatory pathway, precisely: the marketing authorisation is the Autorisation de Mise sur le Marché (AMM), granted through the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML) within the Ministry of Public Health (MINSANTE) on a dossier prepared in CTD format to the CEMAC/OCEAC-harmonised technical requirements. The first authorisation is issued for 18 months and, on renewal filed at least three months before expiry, is extended to five years. CEMAC harmonises the format, but the authorisation is still granted nationally — a product must be registered in Cameroon itself.
The import route, stated plainly: manufacturing, importation and wholesale distribution are reserved by law to licensed établissements pharmaceutiques led by a registered pharmacist, and every consignment needs a Visa Technique d’Importation from MINSANTE against a product that already holds an AMM. An Indian manufacturer cannot import in its own name — it works through a locally licensed, pharmacist-led importer or grossiste-répartiteur.
Documentation runs on consular legalisation, not apostille. Cameroon is not a contracting party to the Hague Apostille Convention, so the Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale must be legalised through the Cameroonian diplomatic chain — a step exporters accustomed to apostille-only markets frequently overlook. Dossiers are prepared in French and labelling is bilingual French and English.
Stability must match the climate. Cameroon sits in ICH Climatic Zone IVb, with long-term storage at 30°C/75% RH. Farbe Firma files the full Zone IVb package as standard, which de-risks distribution across the country’s humid south and lets the same data support registrations in neighbouring CEMAC markets from a single study.
Introduction: Why an Injectable Manufacturer in Cameroon Must Meet Global Standards
Cameroon’s health system serves roughly 30 to 31 million people through a pyramidal structure — central and general hospitals in Yaoundé and Douala at the apex, then ten regional hospitals, district hospitals and a wide base of integrated health centres. Public-sector essential medicines are procured and distributed by the Centrale Nationale d’Approvisionnement en Médicaments et Consommables Médicaux Essentiels (CENAME), reorganised by decree in 2024, which supplies the regional pharmaceutical supply centres (the CAPR / Fonds Régionaux) that in turn serve facilities against the National Essential Medicines List. Alongside the public channel sits a substantial private market served through licensed wholesaler-distributors and community pharmacies. For a sterile injectable supplier, the practical consequence is that a single national registration opens several distinct doors — CENAME international tenders, faith-based supply networks such as the Cameroon Baptist Convention central pharmacy, hospital purchasing and the private wholesale trade — each with its own qualification and contracting rhythm.
The demand behind that structure is heavy. Cameroon is one of the world’s eleven High Burden to High Impact malaria countries, with the World Health Organization estimating around 7.6 million cases and roughly 11,700 deaths in 2024 — a burden that sustains constant need for injectable artesunate and quinine for severe malaria. Maternal mortality remains high, estimated at between 258 and 340 per 100,000 live births depending on the source, keeping oxytocin, magnesium sulphate and injectable antibiotics near the top of any essential list. Cancer already accounts for roughly 19,600 new cases and 12,800 deaths a year, pushing demand toward parenteral oncology, while tuberculosis, HIV and a rising non-communicable-disease burden — now about a third of all deaths — complete the picture. Against all of this, local production covers only about 5% of the market: the country has no domestic maker of small-volume sterile injectables, so more than nine in ten of the injectables it uses are imported. Cameroon needs reliable imported injectables, and it needs them from manufacturers whose quality systems will survive scrutiny.
What Sets a World-Class Injectable Manufacturer in Cameroon Apart
The first differentiator is genuine sterile-manufacturing capability rather than a general plant with a filling line bolted on. Sterile injectables bypass every natural barrier the body has, so sterility assurance cannot be inferred from a finished-product test alone — it has to be designed into the facility. Farbe Firma’s operation in Gujarat, India is built around ISO Class 5 aseptic filling zones within classified surrounding areas, unidirectional personnel and material flows, validated terminal sterilisation or aseptic processing according to the molecule, routine media-fill validation, environmental and personnel monitoring with trended data, and Water-for-Injection generation and distribution held under continuous control. That architecture is what turns a certificate of analysis into a defensible claim — and, because DPML assessment and the IGSPL inspectorate scrutinise exactly this evidence, it is precisely what a Cameroonian dossier is built to present.
The second differentiator is market-access support built around Cameroon’s actual pathway, including the parts that are inconvenient. The marketing authorisation is the Autorisation de Mise sur le Marché, granted through the DPML within the Ministry of Public Health on a dossier prepared in CTD format to the CEMAC/OCEAC-harmonised technical requirements, with a first authorisation of 18 months that renewal extends to five years. CEMAC harmonises the format across the Central African monetary community, but the authorisation is still granted nationally: there is no single community-wide AMM, so the product must be registered in Cameroon itself. Nor can a manufacturer in Gujarat import in its own name — manufacturing, importation and wholesale distribution are reserved to licensed établissements pharmaceutiques led by a registered pharmacist, and every consignment requires a Visa Technique d’Importation. A useful supplier therefore does not simply ship product; it builds the dossier its Cameroonian partner will file, supplies a Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale legalised through the Cameroonian diplomatic chain — because Cameroon is not a party to the Hague Apostille Convention, an apostille is not accepted — and prepares French dossiers and bilingual French-and-English labelling that match the authorisation exactly.
Quality Systems Behind Every Batch We Ship to Cameroon
Every Farbe Firma injectable batch destined for Cameroon is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by HPLC and, where the monograph requires it, GC. Sterility and bacterial endotoxin testing by LAL are performed on every batch, with container-closure integrity and particulate matter assessed against compendial limits, and water content by Karl Fischer titration where the dosage form demands it. Methods are validated to ICH expectations and specifications are set against USP, BP, IP or EP as the market and customer require, with the pharmacopoeial basis stated on the certificate of analysis rather than left implicit.
Behind release testing sits the quality architecture that makes those results meaningful. Stability programmes run on three batches under real-time conditions per ICH Q1A, with photostability per ICH Q1B where the molecule warrants it; for Cameroon, which sits in ICH Climatic Zone IVb, we hold long-term data at 30°C/75% RH — the demanding hot-and-humid condition that also covers distribution across the wider CEMAC region from a single package. Change control, deviation management, CAPA, supplier qualification and annual product quality review operate as a connected system rather than as separate files, and batch records are retained so that any vial can be reconstructed from raw material to release years later. Dossiers are compiled in CTD format re-indexed to the CEMAC order, French artwork and leaflets are prepared to the regulator’s requirements, and the site is maintained in a state of continuous inspection readiness.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Cameroon for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, oncology support, anaesthesia and analgesia, cardiovascular and critical-care molecules, obstetric medicines, vitamins and parenteral-nutrition adjuncts, delivered as liquid vials, ampoules, lyophilised presentations and small-volume parenterals — the categories a Cameroonian essential-medicines basket leans on most heavily, from injectable artesunate and antibiotics to oxytocin and magnesium sulphate. For a Cameroonian établissement assembling a hospital portfolio, or a distributor qualifying for CENAME tenders, that breadth means one audited manufacturing partner, one documentation standard and one point of accountability rather than a patchwork of sources with uneven paperwork.
Our CDMO services scale from a single distributor’s launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer’s brand with technology transfer, analytical method transfer, stability commitment and regulatory documentation handled as one package. We prepare the CTD/CEMAC dossier for the AMM, provide the consular-legalised Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale, prepare French labelling and bilingual inserts for DPML approval, and supply the batch-level certificates of analysis and retention-sample discipline that an importer’s responsible pharmacist needs in order to defend a product line. Because India is already the leading source of Cameroon’s imported medicines, a manufacturer that exports to more than 30 countries brings documentation of exactly the kind the review is designed to accept.
Buyers stay with Farbe Firma because we are straightforward about what the Cameroonian route actually involves. Registration and importation must run through a locally licensed, pharmacist-led établissement holding a Visa Technique d’Importation — a manufacturer cannot import in its own name — and because Cameroon is outside the Hague Apostille Convention, every certificate must be consular-legalised rather than apostilled, a step exporters used to apostille-only markets routinely underestimate. The CEMAC framework harmonises the dossier but does not confer a single regional licence, so each market is registered on its own, and reviews are demanding: a recent performance study of Cameroonian homologation found a median evaluation time of about 197 days and a high rejection rate, so dossier quality is decisive. We are equally candid about the environment: Cameroon has a serious substandard-and-falsified-medicines problem and a large informal market, so a WHO-GMP supplier competes on verifiable quality and documentation rather than on price alone. We would rather set out the local-partner requirement, the legalisation step and the French-language obligations honestly at the first meeting than discover the gap at the point of filing.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Cameroon?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable products under ISO Class 5 aseptic conditions and exporting to over 30 countries. For Cameroon we prepare the CTD dossier to the CEMAC/OCEAC-harmonised requirements, provide a Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale legalised through the Cameroonian diplomatic chain, prepare French dossiers and bilingual French-and-English labelling, and hold Zone IVb stability data. Because importation and wholesale are reserved to licensed, pharmacist-led établissements pharmaceutiques, we work alongside a client’s local importer rather than filing in our own name.
How is an imported injectable registered in Cameroon, and how long is the authorisation valid?
The marketing authorisation is the Autorisation de Mise sur le Marché, granted through the Direction de la Pharmacie, du Médicament et des Laboratoires (DPML) within the Ministry of Public Health. The dossier is prepared in CTD format to the CEMAC/OCEAC-harmonised technical requirements and is filed by a locally licensed établissement pharmaceutique; it must include a Certificate of Pharmaceutical Product in WHO format, a GMP certificate and a Certificate of Free Sale, all consular-legalised, together with quality, stability and French labelling documentation. The first authorisation is issued for 18 months and, on renewal filed at least three months before expiry, is extended to five years. CEMAC harmonises the format but does not grant a single regional licence, so the product must be registered in Cameroon specifically.
Does Cameroon accept an apostille, or is consular legalisation required?
Consular legalisation is required. Cameroon is not a contracting party to the Hague Apostille Convention, so a certificate carrying only an apostille from the country of origin is not sufficient: the Certificate of Pharmaceutical Product, GMP certificate and Certificate of Free Sale must be legalised through the diplomatic and consular chain that serves the exporting country. This is a frequent source of delay for exporters accustomed to apostille-only markets, and Farbe Firma plans the legalisation chain into the registration timeline from the outset. Dossiers are prepared in French and labelling is bilingual French and English.
Which stability data does Cameroon require for sterile injectables?
Cameroon is classified as ICH Climatic Zone IVb, the hot-and-humid zone, with a long-term storage condition of 30°C/75% RH. Farbe Firma builds the full Zone IVb package as standard, with accelerated testing and, where the molecule warrants it, an ICH Q1B photostability challenge. Because 30°C/75% RH is the most demanding of the standard long-term conditions, the same stability data set also supports registrations across the wider CEMAC region, so a dossier prepared for Cameroon travels well to neighbouring Central African markets.
How does public procurement for injectables work in Cameroon?
The principal public channel is the Centrale Nationale d’Approvisionnement en Médicaments et Consommables Médicaux Essentiels (CENAME), the central purchasing body that supplies the regional pharmaceutical supply centres (CAPR / Fonds Régionaux) and buys essential medicines against the National Essential Medicines List through open international tenders. Faith-based networks such as the Cameroon Baptist Convention central pharmacy form a significant second channel. A valid AMM and inclusion on the essential-medicines list are the practical preconditions for public supply, and a product registered in Cameroon can, with the dossier reused, also be taken into neighbouring CEMAC markets.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments